Evidence map›Paper›PMID 26617967›Full record

ArticleACS medicinal chemistry letters2015

Synthesis and Biological Activity of Mono- and Di-N-acylated Aminoglycosides.

Nishad Thamban Chandrika, Keith D Green, Jacob L Houghton, Sylvie Garneau-Tsodikova

Abstract read
In one paragraph

Article in ACS medicinal chemistry letters, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Amikacin: Uses, Resistance, and Prospects for Inhibition.Molecules (Basel, Switzerland) · 2017
    Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Nishad Thamban ChandrikaDepartment of Pharmaceutical Sciences, University of Kentucky , Lexington, Kentucky 40536-0596, United States.
Keith D GreenDepartment of Pharmaceutical Sciences, University of Kentucky , Lexington, Kentucky 40536-0596, United States.
Jacob L HoughtonDepartment of Medicinal Chemistry and Life Sciences Institute, University of Michigan , Ann Arbor, Michigan 48109-2216, United States.
Sylvie Garneau-TsodikovaDepartment of Pharmaceutical Sciences, University of Kentucky , Lexington, Kentucky 40536-0596, United States.
University of Kentucky · USUniversity of Michigan–Ann Arbor · US

Funding

Novel aminoglycoside adjuvants and stand-alone agents to combat tuberculosisR01AI090048 · NIAID · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI GARNEAU-TSODIKOVA, SYLVIE · 2011 to 2021
$4.4M
Cellular Biotechnology Training Program (CBTP) - Years 31-35T32GM145304 · NIGMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Guizhi Zhu · 2022 to 2026
$2.6M
NIAID NIH HHS R01 AI090048NIGMS NIH HHS T32 GM145304
6 · The paper itself

Abstract

Despite issues with oto/nephrotoxicity and bacterial resistance, aminoglycosides (AGs) remain an effective and widely used class of antibacterial agents. For decades now, efforts toward the development of novel AGs with potential to overcome some of these problems have been major research focuses. 1-N-Acylation, especially γ-amino-β-hydroxybutyrate (AHB) derivatization, has proven to be one of the most successful strategies for improving the overall properties of AGs, including their ability to avoid certain resistance mechanisms. More recently, 6'-N-acylation arose as another possible strategy to improve the properties of these drugs. In this study, we report on the glycinyl, carboxybenzyl, and AHB mono- and diderivatization at the 1-, 6'-, and/or 4‴-amines of the AGs amikacin, kanamycin A, netilmicin, sisomicin, and tobramycin. We also present the antibacterial activities and the reduced reactivity of AG-modifying enzymes (AMEs) toward these new AG derivatives, and identify the AMEs present in the bacterial strains tested.

Indexed as

Acylationaminoglycoside antibioticsbacterial resistancedrug developmentdrug-modifying enzymes

Identifiers

PMID26617967
PMCPMC4645238
OpenAlexW2373017901

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.